CR9452A - Agentes terapeuticos a base de peptidos de toxinas - Google Patents

Agentes terapeuticos a base de peptidos de toxinas

Info

Publication number
CR9452A
CR9452A CR9452A CR9452A CR9452A CR 9452 A CR9452 A CR 9452A CR 9452 A CR9452 A CR 9452A CR 9452 A CR9452 A CR 9452A CR 9452 A CR9452 A CR 9452A
Authority
CR
Costa Rica
Prior art keywords
therapeutic agents
agents based
independently
toxin peptides
dye
Prior art date
Application number
CR9452A
Other languages
English (en)
Inventor
K Sullivan John
G Mcgivern Joseph
Q Nguyen Hung
W Walter Kenneth
Sylvia Hu Shaw-Fen
L Mcdonough Stefan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR9452A publication Critical patent/CR9452A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Se revela una composicion de materia que tiene la siguiente formula: (I) (X1)a-(F1)d-(X2)b-(F2)e-(X3)c y sus multimeros, donde F1 y F2 son fracciones que prolongan la semivida, y d y e son cada uno, en forma independiente, 0 o 1, siempre que al menos uno de d y e sea 1; X1, X2 y X3 son cada uno, en forma independiente, -(L)f-P-(L)g-, y f y g son cada uno, en forma independiente, 0 o 1; P es un peptido de toxina de una longitud de no mas de 80 residuos de aminoacidos, aproximadamente, que comprende al menos dos enlaces disulfuro intrapeptidicos; L es un enlazador optativo; y a, b y c sea 1.
CR9452A 2005-04-22 2007-10-19 Agentes terapeuticos a base de peptidos de toxinas CR9452A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67434205P 2005-04-22 2005-04-22
US11/406,454 US7833979B2 (en) 2005-04-22 2006-04-17 Toxin peptide therapeutic agents

Publications (1)

Publication Number Publication Date
CR9452A true CR9452A (es) 2008-05-21

Family

ID=37894298

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9452A CR9452A (es) 2005-04-22 2007-10-19 Agentes terapeuticos a base de peptidos de toxinas

Country Status (16)

Country Link
US (2) US7833979B2 (es)
EP (1) EP1896080A2 (es)
JP (2) JP5087536B2 (es)
KR (2) KR20100017942A (es)
AR (1) AR053234A1 (es)
AU (1) AU2006239928B8 (es)
BR (1) BRPI0607750A2 (es)
CA (1) CA2604999A1 (es)
CR (1) CR9452A (es)
EA (1) EA013470B1 (es)
IL (1) IL186527A0 (es)
MX (1) MX2007013031A (es)
NO (1) NO20076013L (es)
NZ (1) NZ562201A (es)
TW (1) TW200716748A (es)
WO (1) WO2006116156A2 (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB0414272D0 (en) * 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
EP2049138A4 (en) * 2006-07-14 2011-11-09 Georgia Tech Res Inst CLC KANALLIGAND
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
CA2667678A1 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
JP5249319B2 (ja) * 2007-05-14 2013-07-31 ウニヴェルシダ ナシオナル アウトノマ デ メヒコ ヒトＴ−リンパ球カリウムチャンネル（Ｋｖ１．３亜型）を高い選択性で遮断し、ラットにおける生体内でのＤＴＨ−応答を減少させる二つのサソリペプチドＶｍ２３及びＶｍ２４
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2009064815A1 (en) * 2007-11-13 2009-05-22 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
WO2009075773A2 (en) * 2007-12-07 2009-06-18 Goldstein Steven A Identification of toxin ligands
JP2011520914A (ja) 2008-05-15 2011-07-21 トランスモレキュラー， インコーポレイテッド 転移腫瘍の処置
MX2011000861A (es) 2008-07-23 2011-06-21 Hanmi Holdings Co Ltd Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales.
MX2011003117A (es) * 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
US20110171161A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of protegrin peptides
WO2010033222A2 (en) * 2008-09-19 2010-03-25 Netkar Therapeutics Polymer conjugates of ziconotide peptides
US8252228B1 (en) * 2008-10-13 2012-08-28 Abbott Cardiovascular Systems Inc. Methods for sterilizing carriers for treatment of a kidney
MX347291B (es) * 2009-03-20 2017-04-17 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
ES2548030T3 (es) * 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
CA2781532A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
HUE034119T2 (en) * 2010-02-04 2018-01-29 Morphotek Inc Chlorotoxin polypeptides and conjugates and their use
WO2011142858A2 (en) * 2010-05-11 2011-11-17 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
WO2012021648A1 (en) 2010-08-10 2012-02-16 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
EA201370076A1 (ru) 2010-09-22 2013-08-30 Амген Инк. Иммуноглобулины-переносчики и их применение
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
RU2637085C2 (ru) 2011-06-06 2017-11-29 КИНЕТА УАН, ЭлЭлСи Фармацевтические композиции на основе shk и способы их получения и использования
IN2014CN03333A (es) 2011-10-03 2015-07-03 Univ California
WO2013061106A1 (en) * 2011-10-28 2013-05-02 University Of Debrecen Modified peptide toxins
JP6158090B2 (ja) * 2011-10-31 2017-07-05 ダニエル・ジェイ・カポン 非ペプチドヒンジ部含有フレキシブル抗体様分子
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
CA3062003C (en) 2012-05-17 2022-01-11 Extend Biosciences, Inc. Vitamin d as a targeting group for therapeutic peptides
US9102751B2 (en) 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
KR102584005B1 (ko) 2012-10-11 2023-09-27 다이이찌 산쿄 가부시키가이샤 글리신아미드 화합물의 제조 방법
JP6272230B2 (ja) 2012-10-19 2018-01-31 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート
BR112015013525A2 (pt) 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
EP2948559B1 (en) 2013-01-25 2018-05-02 Janssen Biotech, Inc. Kv1.3 antagonists and methods of use
NZ711019A (en) * 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
US9789209B2 (en) 2013-03-14 2017-10-17 The Regents Of The University Of California, Berke Activatable membrane-interacting peptides and methods of use
WO2015010100A2 (en) * 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015013330A2 (en) * 2013-07-22 2015-01-29 Kineta One, Llc Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
ES2841173T3 (es) 2013-10-03 2021-07-07 Janssen Biotech Inc Variantes de Protoxina-II y métodos de uso
US9708377B2 (en) * 2013-10-28 2017-07-18 Monash University Scorpion toxin analogue and method for treating autoimmune diseases
RU2743077C2 (ru) * 2013-12-25 2021-02-15 Дайити Санкио Компани, Лимитед Конъюгат анти-trop2 антитело-лекарственное средство
CN105829346B (zh) 2014-01-31 2019-08-23 第一三共株式会社 抗her2抗体－药物偶联物
WO2015155976A1 (ja) 2014-04-10 2015-10-15 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート
ES2859648T3 (es) 2014-04-10 2021-10-04 Daiichi Sankyo Co Ltd Conjugado anticuerpo-fármaco anti-HER3
GB201408135D0 (en) * 2014-05-08 2014-06-25 Conogenetix Biosciences Gmbh Kv1.3 potassium channel antagonists
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
CN104177489B (zh) * 2014-07-29 2017-03-22 暨南大学 基因重组TNF‑α衍生物RMP16及其制备方法与应用
EP3179857B1 (en) * 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
JP6798998B2 (ja) 2014-11-07 2020-12-09 キネタ・クロニック・ペイン・リミテッド・ライアビリティ・カンパニーＫｉｎｅｔａ Ｃｈｒｏｎｉｃ Ｐａｉｎ， ＬＬＣ コノトキシンペプチドの修飾および使用
WO2016112208A2 (en) * 2015-01-09 2016-07-14 Kineta One, Llp Topical applications of kv1.3 channel blocking peptides to treat skin inflammation
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
EP3277304B1 (en) 2015-04-02 2021-08-04 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
ES2938186T3 (es) 2015-06-29 2023-04-05 Daiichi Sankyo Co Ltd Procedimiento de fabricación selectiva de un conjugado anticuerpo-fármaco
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US10544221B2 (en) 2016-05-20 2020-01-28 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018098354A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
BR112019010602A2 (pt) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc proteínas trispecíficas para psma e métodos de uso
WO2018102777A1 (en) * 2016-12-01 2018-06-07 University Of South Florida Peptibodies, compositions thereof, and methods of treating atrial fibrillation
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3046293A1 (en) 2016-12-12 2018-06-21 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
EP3572428A4 (en) 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited ANTI-GPR20 ANTIBODY AND ANTI-GPR20 ANTIBODY MEDICINAL CONJUGATE
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US10668113B2 (en) 2017-03-31 2020-06-02 Vivekananda Ramana Formulation for targeting cancer in humans and canines using venom
US10668130B2 (en) 2017-03-31 2020-06-02 Vivekananda Ramana Formulation for targeting cancer in humans and canines using chlorotoxin
US10668112B2 (en) 2017-03-31 2020-06-02 Vivekananda Ramana Formulation for targeting cancer in humans and canines
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
US20230331827A1 (en) * 2017-07-12 2023-10-19 Maxion Therapeutics Limited Potassium channel inhibitors
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
WO2019044947A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
CN117838881A (zh) 2017-08-31 2024-04-09 第一三共株式会社 制备抗体-药物缀合物的新方法
US20200262877A1 (en) * 2017-10-09 2020-08-20 Blaze Bioscience, Inc. Ion channel-binding peptides and methods of use thereof
US10927180B2 (en) 2017-10-13 2021-02-23 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
PE20201183A1 (es) 2017-10-13 2020-11-03 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso
EP4257611A3 (en) 2018-05-18 2024-03-06 Glycotope GmbH Anti-muc1 antibody
WO2019225296A1 (ja) * 2018-05-24 2019-11-28 国立大学法人熊本大学 薬物送達用担体
IL297931A (en) 2018-09-25 2023-01-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
TW202116350A (zh) 2019-09-20 2021-05-01 丹麥商西蘭製藥公司 Kv1.3阻斷劑
JP2023527609A (ja) 2020-02-21 2023-06-30 ハープーン セラピューティクス，インク． Ｆｌｔ３結合タンパク質および使用方法
WO2022066767A2 (en) 2020-09-23 2022-03-31 Aldevron, Llc Potent and selective inhibitors of nav1.7
CN112353934B (zh) * 2020-11-23 2023-05-19 中国人民解放军军事科学院军事医学研究院 一种芋螺毒素药物组合物及其冻干制剂
JP2024511449A (ja) 2021-03-23 2024-03-13 ジーランド ファーマ エー／エス Ｋｖ１．３遮断薬
WO2024083919A1 (en) 2022-10-18 2024-04-25 Zealand Pharma A/S Inhibitors

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
JPH0669959B2 (ja) 1985-09-26 1994-09-07 東燃株式会社 コレラ毒素類を活性成分とする免疫抑制剤
AU607172B2 (en) 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
ATE81467T1 (de) 1987-02-24 1992-10-15 Xoma Corp Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4925677A (en) 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5397702A (en) 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US4994436A (en) * 1989-03-10 1991-02-19 American Air Liquide Process for safely destroying organic binders in ceramic components during the firing process
US4906159A (en) 1989-03-22 1990-03-06 Caterpillar Industrial Inc. Freely positionable load carrying attachment for an automatic guided vehicle
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
IL98932A0 (en) 1990-07-27 1992-07-15 Univ California Assay,kits and methods based on nk+channel expression
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
JPH0640945A (ja) 1992-07-23 1994-02-15 Kureha Chem Ind Co Ltd Ｆｃフラグメント結合抗腫瘍剤
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5494895A (en) 1993-07-22 1996-02-27 Merck & Co., Inc. Scorpion peptide margatoxin with immunosuppressant activity
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
CA2184002A1 (en) 1994-02-23 1995-08-31 Jeffrey M. Blaney Method and compositions for increasing the serum half-life of pharmacologically active agents
FR2717688B1 (fr) 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ATE236617T1 (de) 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5763478A (en) 1996-10-16 1998-06-09 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
US6077680A (en) 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
EP0916681B1 (en) 1996-12-26 2005-10-26 Suntory Limited Neuropeptides originating in scorpion
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
SG129211A1 (en) 1997-11-06 2007-02-26 Univ Singapore Therapeutic molecules
US6703485B2 (en) 1997-12-23 2004-03-09 The Trustees Of Columbia University In The City Of New York Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
US6551821B1 (en) 1997-12-23 2003-04-22 The Trustees Of Columbia University In The City Of New York Brain cyclic nucleotide gated ion channel and uses thereof
JP3515072B2 (ja) 1998-01-23 2004-04-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成長因子模倣物質、成長因子および阻害因子の同定に用いられる方法および組成物
JP3530004B2 (ja) 1998-02-06 2004-05-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6166322A (en) * 1999-04-16 2000-12-26 Industrial Technology Research Institute Encapulation process for mono-and polycrystalline silicon solar cell modules
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CA2623458A1 (en) 1999-05-17 2000-11-23 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AR024436A1 (es) 1999-06-22 2002-10-02 Du Pont Toxinas de escorpion
US6768002B1 (en) 1999-06-22 2004-07-27 E. I. Du Pont De Nemours And Company Scorpion toxins
US6096891A (en) 1999-12-09 2000-08-01 Air Products And Chemicals, Inc. Process for the production of cyclic N,N'-dialkylureas
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
SE0000935D0 (sv) 2000-03-21 2000-03-21 Astrazeneca Ab An inhalation device
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
AU5943201A (en) 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
EP1177806A1 (en) 2000-08-04 2002-02-06 The Technology Partnership Public Limited Company Dry powder inhaler
RU2363707C2 (ru) * 2001-02-19 2009-08-10 Мерк Патент Гмбх Искусственные белки с пониженной иммуногенностью
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6861405B2 (en) 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7737260B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2004043396A2 (en) 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
SI1641483T1 (sl) 2003-06-12 2008-08-31 Lilly Co Eli Fuzijski proteini
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
BRPI0516011A (pt) 2004-09-24 2008-08-19 Amgen Inc moléculas fc modificadas
US8080523B2 (en) 2004-10-07 2011-12-20 The Regents Of The University Of California Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
CA2667678A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
MX347291B (es) 2009-03-20 2017-04-17 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.

Also Published As

Publication number Publication date
IL186527A0 (en) 2008-01-20
US8907071B2 (en) 2014-12-09
NO20076013L (no) 2008-01-22
JP2008538506A (ja) 2008-10-30
CA2604999A1 (en) 2006-11-02
KR20100017942A (ko) 2010-02-16
AU2006239928A1 (en) 2006-11-02
BRPI0607750A2 (pt) 2009-11-24
KR20080021606A (ko) 2008-03-07
NZ562201A (en) 2011-03-31
EP1896080A2 (en) 2008-03-12
AU2006239928B2 (en) 2010-12-02
JP2012100671A (ja) 2012-05-31
JP5087536B2 (ja) 2012-12-05
AR053234A1 (es) 2007-04-25
JP5220915B2 (ja) 2013-06-26
US20070071764A1 (en) 2007-03-29
EA013470B1 (ru) 2010-04-30
TW200716748A (en) 2007-05-01
US7833979B2 (en) 2010-11-16
US20110045587A1 (en) 2011-02-24
MX2007013031A (es) 2007-12-12
EA200702313A1 (ru) 2008-06-30
WO2006116156A3 (en) 2007-10-04
AU2006239928B8 (en) 2011-03-31
WO2006116156A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
CR9452A (es) Agentes terapeuticos a base de peptidos de toxinas
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
NO20026252D0 (no) AZA-broforbundet - bicykliske aminosyrederivater som alfa 4 integrin antagonister
NO20073244L (no) Konjugeringsprodukt
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
MXPA05003730A (es) Eritropoyetina: remodelado y glicoconjugacion de eritropoyetina.
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
ES2160485B1 (es) Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
CO5560528A2 (es) Agentes de contraste de objetivo multimetrico con base en peptidos
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
DK1163239T3 (da) Modificerede aminosyreamider som CGRP-antagonister
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ES2162231T3 (es) Nuevos derivados de n-(arilsulfonil)aminoacidos que tienen afinidad con los receptores de bradicinina.
ATE235510T1 (de) Integrinbindendes peptid und dessen verwendung
IS8308A (is) Amínósýrur með sækni fyrir a2o prótíninu
ATE452646T1 (de) Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat
NO20025114D0 (no) Trombopoitein reseptor-modulerende peptid
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
PE20010516A1 (es) Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina
DE50010265D1 (de) Azidfreie gaserzeugende Zusammensetzung
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)